Company to submit delisting request to Nasdaq
Paris (France), August 17, 2022 – 8:00 p.m. CEST – Onxeo SA (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereinafter “Onxeo” or “the Company”, a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, announces that the Combined General Meeting held today adopted all of the resolutions presented in line with the recommendations of the Board of Directors.
The shareholders notably approved the delisting of the Company’s shares from the Nasdaq First North market in Copenhagen and granted all powers to the Board of Directors to carry out the delisting.
The company will formally request, in the coming days, the delisting of the Nasdaq First North from the Danish stock market operator.
After market operator approval, the shares will be effectively delisted from the Nasdaq First North market after an additional 10 weeks.
To receive all of ONXEO’s financial information in real time, send a request by email to [email protected]. Your registration will be immediate.